Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention
暂无分享,去创建一个
S. Pocock | T. Henry | M. Krucoff | G. Dangas | G. Weisz | R. Mehran | A. Kini | U. Baber | A. Colombo | B. Vogel | B. Claessen | D. Cohen | C. Gibson | P. Steg | D. Moliterno | S. Sartori | R. Chandiramani | J. Chandrasekhar | B. Witzenbichler | P. Urban | S. Sorrentino | P. Guedeney | G. Giustino | A. Chieffo | C. Ariti | D. Cohen | C. Gibson
[1] M. Price,et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. , 2019, American heart journal.
[2] F. Costa,et al. Characterization of the Individual Patient Risk After Percutaneous Coronary Intervention: At the Crossroads of Bleeding and Thrombosis. , 2019, JACC. Cardiovascular interventions.
[3] A. Íñiguez,et al. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study , 2019, American heart journal.
[4] Deepak L. Bhatt,et al. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.
[5] S. Pocock,et al. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). , 2018, The American journal of cardiology.
[6] M. Price,et al. Rationale and design of the EVOLVE Short DAPT Study to assess 3‐month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention , 2018, American heart journal.
[7] Samin K. Sharma,et al. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention , 2018, Thrombosis and Haemostasis.
[8] P. Serruys,et al. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. , 2018, JACC. Cardiovascular interventions.
[9] P. Kolh,et al. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.
[10] Deepak L. Bhatt,et al. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. , 2017, Journal of the American College of Cardiology.
[11] S. Pocock,et al. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. , 2017, Journal of the American College of Cardiology.
[12] C. Held,et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.
[13] S. Pocock,et al. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. , 2016, JACC. Cardiovascular interventions.
[14] Samin K. Sharma,et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.
[15] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[16] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[17] S. Pocock,et al. A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.
[18] S. Pocock,et al. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial , 2010, Circulation.
[19] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.